Murine Model Study of a New Receptor-Targeted Tracer for Sentinel Lymph Node in Breast Cancer.
Chonglin TianXiao SunBinbin CongPengfei QiuYong-Sheng WangPublished in: Journal of breast cancer (2019)
ICG-rituximab localized to the SLN without imaging from the secondary or tertiary LNs within 6 hours. The optimal ICG dose was 0.12 μg, and the optimal interval for SLN detection was 34 minutes to 6 hours post-injection. This novel receptor-targeted tracer is of great value to clinical research and application.
Keyphrases
- sentinel lymph node
- early stage
- lymph node
- fluorescence imaging
- neoadjuvant chemotherapy
- cancer therapy
- high resolution
- positron emission tomography
- pet imaging
- diffuse large b cell lymphoma
- loop mediated isothermal amplification
- photodynamic therapy
- binding protein
- label free
- computed tomography
- radiation therapy
- mass spectrometry
- locally advanced